Abstract: Objective To investigate the clinicopathological significances of Integrin α6 expression in Gliobastoma multiforme (GBM). Methods Integrin α6 expression was assessed in 39 cases of paraffin-embedded GBM and 32 cases of normal samples by immunohistochemistry. Medical records were reviewed and the clinicopathological characteristics or outcomes were evaluated. Furthermore, we examined the association of the Integrin α6 expression with the CD133 expression, which was a marker of glioblastoma stem cells (GSCs). Results Integrin α6 expression was significantly higher in GBM than in normal brain tissue (P<0.01). Integrin α6 was positively correlated with the expression of CD133 (P<0.05) and negatively correlated with the tumor size and subtotal resection and had no significant relationship with patients' age, gender, KPS assessment and postoperative radiochemotherapy. For the patients with positive Integrin α6 expression in GBM, their overall survival time was obviously shorter than those with negative expression (χ²=4.388,P<0.05). Conclusion The overexpression of Integrin α6 is linked to GBM development and progression and is significantly correlated with GSCs. Hence, the expression levels of Integrin α6 is an useful indicators for the clinical assessment of tumor biological behavior in patients with GBM.